

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM523960

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
SUN PHARMACEUTICAL INDUSTRIES LIMITED		08/15/2018	Limited Liability Company: INDIA
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	THERAPEUTICS, INC.		
<b>Street Address:</b>	9025 Balboa Avenue, Suite 100		
<b>City:</b>	San Diego		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	92123		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 1</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	87705048	CLAAVA	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>			
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	858-800-2537		
<b>Email:</b>	kristen@ns-lg.com		
<b>Correspondent Name:</b>	JONATHAN A. MUENKEL		
<b>Address Line 1:</b>	12636 HIGH BLUFF DRIVE, SUITE 400		
<b>Address Line 2:</b>	NORTHSTAR LAW GROUP		
<b>Address Line 4:</b>	SAN DIEGO, CALIFORNIA 92130		
<b>ATTORNEY DOCKET NUMBER:</b>	102-00001		
<b>NAME OF SUBMITTER:</b>	Kristen lemme		
<b>SIGNATURE:</b>	/Kristen Lemme/		
<b>DATE SIGNED:</b>	05/16/2019		
<b>Total Attachments: 2</b>			
source=102-00001 SUN - TI _ CLAAVA TM Assignment (FE 051419)#page1.tif			
source=102-00001 SUN - TI _ CLAAVA TM Assignment (FE 051419)#page2.tif			

OP \$40.00 87705048

**TRADEMARK ASSIGNMENT**

This Trademark Assignment ("Assignment") is made as of 15 August 2018 ("Effective Date"), by and between Sun Pharmaceutical Industries Limited (hereinafter referred to as "Assignor"), and Therapeutics, Inc. (hereinafter referred to as "Assignee").

WHEREAS, Assignor is the sole and exclusive owner of the entire right, title and interest in, to and under the trademarks listed in Schedule A attached herewith, and all other rights appurtenant thereto, including, but not limited to, all common law rights, trade name rights, causes of action, and the right to recover for past infringement (collectively, the "Trademarks"); and

WHEREAS, Assignor and Assignee have entered into a Settlement Agreement dated August 14, 2018 (the "Settlement Agreement"), under which Assignor agreed to assign all of the Assignor's right, title and interest in and to the Trademarks, together with any and all goodwill associated therewith, and based on the fact that Assignee is the successor to the entire portion of the ongoing and existing business to which the Trademarks pertain.

NOW, THEREFORE, for good and adequate consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor hereby assigns and sells to Assignee, all rights, title, and interest as Assignor may possess in and to the Trademarks together with the goodwill of the Trademarks, including any renewals or extensions thereof that are or may be secured under the laws of the United States or foreign countries now or hereafter in effect for its own use and enjoyment, and for the use and enjoyment of its successors, assigns or other legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor if this Assignment and sale had not been made; including all claims for damages by reason of past, present or future infringement or other unauthorized use, with the right to sue for, and collect the same for its own use and enjoyment, and for the use and enjoyment of its successors, assigns, or other legal representatives.

This Assignment and its terms shall be construed, interpreted and applied in accordance with the laws of the State of California, without regard to its conflicts of law principles.

IN WITNESS WHEREOF, Assignor has caused this Assignment to be executed by its duly authorized officer on the date first above written.

**ASSIGNOR:**

**ASSIGNEE:**

**Sun Pharmaceutical Industries Limited**

**Therapeutics, Inc.**

By: \_\_\_\_\_

By: \_\_\_\_\_

Name: Craig Kuchii

Name: Daniel J. Picquadio, M.D.

Title: Senior Director, Intellectual Property

Title: Chief Executive Officer



**SCHEDULE A**

<b>Trademark</b>	<b>Country</b>	<b>Application No.</b>	<b>Filing Date</b>
CLAAVA	US	87/705,048	1 December 2017
CLAAVA	India	3687094	24 November 2017